AVTXHIGH SIGNALFINANCIAL10-K

AVTX experienced a dramatic cash burn with cash equivalents falling from $134.5M to $15.9M while liabilities nearly doubled, indicating severe liquidity pressure for this clinical-stage biotech.

The company burned through approximately $119M in cash over the year while substantially reducing SG&A expenses, suggesting aggressive cost-cutting measures in response to funding constraints. The doubling of outstanding shares from 10.7M to 22.8M indicates significant equity dilution, likely from emergency financing activities to address the cash crisis.

Comparing 2026-03-23 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

AVTX's financial position deteriorated markedly, with cash reserves plummeting 88% to just $15.9M while total liabilities nearly doubled to $33.4M. The company meaningfully reduced SG&A spending by half while modestly increasing R&D investment, indicating prioritization of core development programs amid severe cost pressures. The overall picture signals a clinical-stage biotech in financial distress, having burned through most of its cash runway and requiring immediate capital infusion to continue operations.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
+88.8%
$17.7M→$33.4M

Liabilities grew 88.8% — significant increase in debt or obligations, assess impact on financial flexibility.

Cash & Equivalents
Balance Sheet
-88.2%
$134.5M→$15.9M

Cash declined 88.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Liabilities
Balance Sheet
+85.9%
$7.0M→$12.9M

Current liabilities surged 85.9% — significant near-term obligations; verify ability to meet short-term debt.

SG&A Expense
P&L
-50.3%
$20.7M→$10.3M

SG&A reduced 50.3% — improved cost efficiency or headcount reduction improving operating margins.

Stockholders Equity
Balance Sheet
-37.6%
$133.0M→$83.0M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

R&D Expense
P&L
+32.3%
$4.4M→$5.8M

R&D investment increased 32.3% — signals commitment to future product development, though near-term margin impact.

Current Assets
Balance Sheet
-24.2%
$138.9M→$105.3M

Current assets declined 24.2% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-22.7%
$150.7M→$116.5M

Total assets contracted 22.7% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-23
PRIOR — 2025-03-20
ADDED
As of March 18, 2026, there were 22,788,452 outstanding shares of the registrant s common stock, par value $0.001 per share.
A more complete statement of those risks and uncertainties is set forth under Part I, Item 1A Risk Factors of this Annual Report on Form 10-K.
Even if we complete the necessary clinical trials, we cannot predict when or if we will obtain marketing approval to commercialize a product candidate or the approval may be for a narrower indication than we expect or may be conditioned on costly post-approval obligations.
Our focus and reliance on abdakibart (AVTX-009) increases the risk of such exposure.
Our focus and reliance on abdakibart (AVTX-009) increases the risk of such exposure.
Our inability to obtain regulatory approval for our product candidates would substantially harm our business and prospects.
This may increase the risk that we will not have sufficient clinical or commercial quantities of our product candidates, or such quantities at an acceptable cost, which could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates and could harm our business, financial condition and results of operations.
Failure to obtain any necessary capital could force us to delay, limit or terminate our product development efforts or significantly curtail or cease our operations altogether.
Even if we receive marketing approval for abdakibart (AVTX-009) or future product candidates, our current or future product candidates may not achieve broad market acceptance, which would limit the revenue that we generate from their sales and could prevent us from achieving or sustaining profitability.
Furthermore, our US composition-of-matter patent for abdakibart (AVTX-009) expired in February 2026.
REMOVED
As of March 17, 2025, there were 10,671,934 outstanding shares of the registrant s common stock, par value $0.001 per share.
A more complete statement of those risks and uncertainties is set forth under Part I, Item 1A Risk Factors of this annual report.
If we are unable to enroll appropriate subjects in clinical trials or retain patients in the clinical trials we perform, we may not be able to complete these trials on a timely basis, or at all.
Our focus and reliance on AVTX-009 increases the risk of such exposure.
Our focus and reliance on AVTX-009 increases the risk of such exposure.
Our inability to obtain regulatory approval for our product candidates would substantially harm our business.
This may increase the risk that we will not have sufficient quantities of our product candidates to conduct our clinical trials or for commercial production or whether we can acquire such quantities at an acceptable cost, which could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates.
Failure to obtain any necessary capital could force us to delay, limit or terminate our product development efforts or cease our operations.
Furthermore, our patent for AVTX-009 is set to expire in 2026.
If we breach the license and development agreements related to our product candidates, we could lose the ability to develop and commercialize our product candidates.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →